Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2010 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, Reinsmoen NL, Villicana R, Jordan SC. Vo AA, et al. Transplantation. 2010 May 15;89(9):1095-102. doi: 10.1097/TP.0b013e3181d21e7f. Transplantation. 2010. PMID: 20110854
BACKGROUND.: We have shown that high-dose intravenous immune globulin (IVIG; 2 g/kg x2 doses)+rituximab (1 g x2 doses) was effective in lowering anti-human leukocyte antigen (HLA) antibodies and improving rates of transplantation. ...METHODS.: F …
BACKGROUND.: We have shown that high-dose intravenous immune globulin (IVIG; 2 g/kg x2 doses)+rituximab (1 g x2 …
Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab.
Vo AA, Wechsler EA, Wang J, Peng A, Toyoda M, Lukovsky M, Reinsmoen N, Jordan SC. Vo AA, et al. Am J Transplant. 2008 Jan;8(1):144-9. doi: 10.1111/j.1600-6143.2007.02017.x. Epub 2007 Oct 31. Am J Transplant. 2008. PMID: 17973966 Free article.
Here we report on our experience with subcutaneous (SQ) Alemtuzumab in an uncontrolled study in highly HLA-sensitized patients (HS). From 3/05-4/07, 54 HS patients received Alemtuzumab 30 mg SQ as induction. ...Patient and graft survival …
Here we report on our experience with subcutaneous (SQ) Alemtuzumab in an uncontrolled study in highly HLA-sensitized
Overcoming the Immunological Barrier in Highly HLA Sensitized Renal Transplant Recipients - A Desensitization Experience from a Transplant Center in Pakistan.
Mirza S, Mahmud SN, Abideen ZU, Aziz T, Akhter S, Baloch BK. Mirza S, et al. J Pak Med Assoc. 2019 Apr;69(4):584-587. J Pak Med Assoc. 2019. PMID: 31000868
In the last few years with the development of immunomodulatory therapies and advancements in immunological investigations, the chance s of transplantation in these sensitized patients have improved. Desensitization therapies in these patients include p …
In the last few years with the development of immunomodulatory therapies and advancements in immunological investigations, the chance s of …